Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Roxifiban inhibits platelet aggregation dose-dependently in CAD patients

Aug. 30, 2000

Safety and efficacy data reported on AstraZeneca's P2T receptor antagonist in PTCA

Aug. 30, 2000

Novel factor Xa inhibitors under development for thromboembolic disorders

Aug. 24, 2000

GlycoDesign and Leo Denmark form joint venture to develop cardiovascular drugs

Aug. 24, 2000

Newly issued patents cover related series of novel amides

Aug. 23, 2000

Novel thrombin inhibitors under study at LG Chemical

Aug. 21, 2000

Safety of clopidogrel shown to be superior to ticlopidine after coronary stenting

Aug. 21, 2000

Orally bioavailable benzthiazolylalanine thrombin inhibitors developed

Aug. 16, 2000

Factor Xa inhibitors under study at Aventis useful for thromboembolic diseases

Aug. 11, 2000

Kogenate Bayer approved in E.U. for hemophilia A

Aug. 9, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...